Welcome to our dedicated page for Merit Medical Systems news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Medical Systems stock.
Merit Medical Systems Inc (NASDAQ: MMSI) is a leading manufacturer of medical devices used in diagnostic and interventional cardiology, radiology, and endoscopy procedures. Headquartered in South Jordan, Utah, the company employs approximately 7,000 individuals globally. Merit Medical's extensive product portfolio includes inflation devices for angioplasty and stent placement, diagnostic and therapeutic catheters, guide wires, thrombolytic catheters, fluid dispensing systems, angiography accessories, and custom angiography kits. The company's products are marketed across the United States, Europe, and around the world through direct sales forces and distributors.
Merit Medical operates primarily in two segments: Cardiovascular, which constitutes the majority of its revenue, and Endoscopy. The company is renowned for its innovative healthcare technology, with recent notable achievements including FDA 510(k) clearance for their SCOUT® MD™ Surgical Guidance System, designed to enhance the precision of tumor excision in breast cancer surgeries.
In 2024, Merit Medical commenced the MOTION study, a multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for treating knee osteoarthritis. This study underscores the company's commitment to evidence-based medicine and patient-centric care. Additionally, the company recently launched the Micro ACE Advanced Micro-Access System and the Siege Vascular Plug, which are expected to significantly improve patient outcomes in vascular procedures.
Financially, the company has introduced a Continued Growth Initiatives Program with robust targets set for 2026. Merit Medical has consistently focused on innovation, investment in research, and strategic expansion, making it a pivotal player in the medical technology sector.
For the latest updates and detailed financial data, Merit Medical Systems regularly schedules earnings calls and provides comprehensive reports which can be accessed by interested stakeholders.
Merit Medical Systems has received FDA Breakthrough Device Designation for its SCOUT MD Surgical Guidance System, enhancing surgical precision for breast and soft tissue cancer treatments. This innovative system allows the implantation of up to four unique reflector configurations, improving tumor localization and minimizing damage to healthy tissue, thereby reducing the need for repeat surgeries. With breast cancer being the most common cancer globally, representing 12.5% of new cases, the SCOUT MD aims to optimize surgical outcomes and patient care. Merit commits to advancing oncology technologies, enhancing patient experiences in cancer treatment.
Merit Medical Systems, Inc. (NASDAQ: MMSI) has announced that it will release its financial results for the fourth quarter and full year of 2022 on February 22, 2023, following the market close. Alongside this, the company will provide guidance for fiscal year 2023. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern time.
Merit is known for its healthcare technology solutions, serving hospitals globally with a dedicated workforce of over 7,100 employees across various locations, including the U.S. and several countries in Europe, Asia, and South America.
Merit Medical Systems (NASDAQ: MMSI) has successfully enrolled its first patient in a new observational study of EmboCube Embolization Gelatin, a product designed to control bleeding during trauma. This minimally-invasive embolization technique is crucial as uncontrolled bleeding is a leading cause of preventable death globally. The EmboCube, which offers uniformly pre-cut gelatin foam for efficient delivery, is currently approved in Europe and Canada but not yet in Australia. The study aims to enroll 100 patients across Australia and France.
Merit Medical Systems has launched the basixALPHA™ Inflation Device for angioplasty procedures, aiming to enhance efficiency and ease of use. This ergonomic device allows for one-handed preparation and fast inflation, crucial for opening blocked arteries and enhancing blood flow to the heart. With over 10 million procedures completed using Merit’s inflation devices, this innovation continues the company's leadership in healthcare technology. The basixALPHA is part of a robust portfolio supporting the annual 1.2 million coronary angioplasties conducted in the U.S.
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced that its Chairman and CEO, Fred Lampropoulos, received the 2022 Manufacturing Leader of the Year Award from the Utah Manufacturers Association. The award recognizes excellence in leadership within Utah’s manufacturing sector. Lampropoulos highlighted the challenges of supply chain interruptions but emphasized the company's innovative responses to continue product delivery. With over 30 years in operation, Merit has grown its revenue to over $1 billion and maintains ISO certifications across its global manufacturing facilities.
Merit Medical Systems has reached a settlement in the derivative action, Maute v. Lampropoulos, resolving claims against former directors for allegedly breaching fiduciary duties through misleading statements regarding the integration of Cianna Medical and ClariVein assets. The settlement hearing is set for February 16, 2023, to assess the fairness and adequacy of the settlement terms. Merit will implement governance reforms as detailed in the stipulation. Both Merit and the Individual Defendants deny wrongdoing and liability.
Merit Medical Systems has appointed Joe Wright as its new Chief Commercial Officer, overseeing global commercial activities. With over 17 years at Merit, most recently as President of International, Wright brings extensive leadership experience across various regions. This restructuring aims to enhance alignment and strengthen commercial capabilities, supporting the company's growth strategy. Chairman Fred P. Lampropoulos emphasized Wright's track record of driving growth and innovation, crucial for improving patient outcomes.
Merit Medical Systems, Inc. (MMSI) reported Q3 2022 revenue of $287.2 million, a 7.5% increase from Q3 2021, with a 10.5% rise in constant currency revenue. The company achieved a GAAP operating margin of 6.5% and a non-GAAP operating margin of 16.1%. GAAP EPS rose to $0.27 from $0.21, while non-GAAP EPS increased to $0.64 from $0.52. Updated 2022 guidance estimates net sales between $1.145-$1.151 billion, reflecting confidence in ongoing growth and profitability.
Merit Medical Systems (NASDAQ: MMSI) announced it will release its financial results for Q3 2022 on October 26, 2022, after the market close. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern. Interested parties can pre-register for the call, and a live webcast will be available. Founded in 1987, Merit is a global leader in healthcare technology, employing over 6,900 individuals across multiple countries.
Merit Medical Systems has launched the TEMNO Elite™ Soft Tissue Biopsy System, designed to improve biopsy procedures. It provides 72% larger samples compared to competitors, ensuring better diagnostic accuracy. The device features Sample Assist™ technology for easier tissue retrieval and includes an optional valved coaxial introducer for enhanced patient safety. This innovation reinforces Merit’s commitment to advancing patient care and improving diagnostic processes in pathology labs.
FAQ
What is the current stock price of Merit Medical Systems (MMSI)?
What is the market cap of Merit Medical Systems (MMSI)?
What does Merit Medical Systems Inc specialize in?
Where is Merit Medical Systems headquartered?
What are the main product segments of Merit Medical Systems?
What recent study has Merit Medical initiated?
What is the SCOUT® MD™ Surgical Guidance System?
How does Merit Medical distribute its products?
What is the significance of the Micro ACE Advanced Micro-Access System?
What is the Siege Vascular Plug used for?
What is Merit Medical's employment size?
What are some of the financial initiatives of Merit Medical?
